Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Neuropsychiatric adverse event reporting with GLP-1-based therapies: a post-marketing pharmacovigilance analysis using the WHO global individual case safety report database (VigiBase)
BMC pharmacology & toxicology, 2026;27(1)
Accidental intradermal injection of tirzepatide associated with increased adverse events
Postgraduate medical journal, 2026
Impact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination – The REST trial study protocol
PloS one, 2026;21(7):e0354237
Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026
Semaglutide and Other GLP-1 Agonists for Antipsychotic-Associated Metabolic Dysfunction in Schizophrenia: A Systematic Review and Meta-Analysis
Journal of clinical psychopharmacology, 2026
Trends in publicly subsidized and private access to GLP-1 medicines indicated for type 2 diabetes in Australia, 2020-2025
British journal of clinical pharmacology, 2026
The cost-effectiveness of second line diabetes medication added to standard therapy in preventing type 2 diabetes related nephropathy in Germany
Cost effectiveness and resource allocation : C/E, 2026;24(1)
“Examining the Impact of Perioperative Glucagon-Like-Peptide-1 use within Foot and Ankle Surgery: A Systematic Review of Comparative Studies”
The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons, 2026
GLP-1 receptor agonists in adolescent obesity: Incretin-based therapies during a sensitive developmental period
Appetite, 2026;:108729
GLP-1 receptor agonists in primary care: readiness, equity, and the risk of a two-tiered obesity treatment landscape
Therapeutic advances in endocrinology and metabolism, 2026;17:20420188261472587
Beyond the Scale: Changes in Pain, Physical Function (WOMAC), and Low-Grade Inflammation Following Semaglutide Treatment in Patients with Knee Osteoarthritis-Results from a Six-Month Real-World Cohort
Journal of clinical medicine, 2026;15(15)
Tirzepatide-Associated Severe Hepatocellular Injury: A Case Report and Diagnostic Considerations
Diagnostics (Basel, Switzerland), 2026;16(15)
Weight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery
Cureus, 2026;18(7):e113460
Glucagon-like Peptide-1 Receptor Agonists and Upper Gastrointestinal Endoscopy: A Narrative Review of Residual Gastric Contents Aspiration Risk and Periprocedural Management
Euroasian journal of hepato-gastroenterology, 2026;16(1):112-118
A Case of Severe Hypercalcemia in a Patient Taking Tirzepatide: Potential Risk Factors
Cureus, 2026;18(7):e113391
Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)
Diabetes, obesity & metabolism, 2026
A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States
PharmacoEconomics, 2026
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1
Diabetes, obesity & metabolism, 2026
Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment
Medicine;105(30):e49916
Nutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis
Diabetes & metabolic syndrome, 2026;20(7):103466